Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study

Background/Aims Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn’s disease (CD) p...

Повний опис

Бібліографічні деталі

Автори:	Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Korean Association for the Study of Intestinal Diseases 2022-04-01
Серія:	Intestinal Research
Предмети:	s100a12 protein calprotectin crohn disease
Онлайн доступ:	http://www.irjournal.org/upload/pdf/ir-2021-00020.pdf
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!